An open label, randomised, multicentre, comparative trial of 5 years adjuvant exemestane treatment versus adjuvant tamoxifen followed by exemestane in postmenopausal women with early breast cancer.

Trial Profile

An open label, randomised, multicentre, comparative trial of 5 years adjuvant exemestane treatment versus adjuvant tamoxifen followed by exemestane in postmenopausal women with early breast cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Exemestane (Primary) ; Tamoxifen
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms TEAM
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Jul 2017 10-year long-term follow up results (n=6120) published in the Lancet Oncology
    • 12 Dec 2015 Results of subgroup analysis from UK TEAM cohort presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 01 Jul 2012 Results from a Dutch QOL substudy published in the Breast Cancer Research and Treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top